Effects of 5-FU

Advances in Experimental Medicine and Biology

Volumn 678, Issue , 2010, Pages 157-164

  Wigmore, Peter M ^a   Mustafa, Sarah ^a   El Beltagy, Maha ^a   Lyons, Laura ^a   Umka, Jariya ^a   Bennett, Geoff ^a  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; CELL MARKER; CYCLOPHOSPHAMIDE; DOUBLECORTIN; DOXORUBICIN; EPIRUBICIN; FLOXURIDINE PHOSPHATE; FLUOROURACIL; METHOTREXATE; THIOTEPA; THYMIDINE PHOSPHATE; THYMIDYLATE SYNTHASE; ANTINEOPLASTIC AGENT;

APOPTOSIS; ARTICLE; ATAXIA; BRAIN DISEASE; BRAIN REGION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CELL PROLIFERATION; CEREBELLUM DISEASE; COGNITIVE DEFECT; CONDITIONING; CONFUSION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG STRUCTURE; EYE DISEASE; HUMAN; LOW DRUG DOSE; MAZE TEST; MEMORY DISORDER; MENTAL FUNCTION; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PRIORITY JOURNAL; PSYCHOMETRY; SENSORY GATING; SPATIAL MEMORY; VERBAL MEMORY; ANIMAL; ANIMAL MODEL; CHEMISTRY; COGNITION;

RODENTIA;

ANIMALS; ANTINEOPLASTIC AGENTS; COGNITION; FLUOROURACIL; HUMANS; MODELS, ANIMAL;

EID: 77956624164     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-6306-2_20     Document Type: Article

References (63)

1. Heidelberger C, Chaudhuri NK, Danneberg P et al. Fluorinated pyrimidines, a new class of tumourinhibitory compounds. Nature 1957; 179(4561):663-666.
2. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003; 3(5):330-338. (Pubitemid 37328853)
3. Backus HH, Rustum YM, van Groeningen CJ et al. Chemotherapeutic strategies for treatment of colorectal cancer: present and future developments. Clin Colorectal Cancer 2001; 1(2):121-127.
4. Iacopetta B, Kawakami K, Watanabe T. Predicting clinical outcome of 5-fluorouracil-based chemotherapy for colon cancer patients: is the CpG island methylator phenotype the 5-fluorouracil-responsive subgroup? Int J Clin Oncol 2008; 13(6):498-503.
5. Parker WB, Cheng YC. Metabolism and mechanism of action of 5-fluorouracil. Pharmacol Ther 1990; 48(3):381-395.
6. Pinedo HM, Peters GF. Fluorouracil: biochemistry and pharmacology. J Clin Oncol 1988; 6(10):1653-1664.
7. Chu E, Callender MA, Farrell MP et al. Thymidylate synthase inhibitors as anticancer agents: from bench to bedside. Cancer Chemother Pharmacol 2003; 52(Suppl 1):S80-89. (Pubitemid 37047028)
8. Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 1989; 16(4):215-237. (Pubitemid 19114713)
9. Celio LA, DiGregorio GJ, Ruch E et al. 5-Fluorouracil concentrations in rat plasma, parotid saliva and bile and protein binding in rat plasma. J Pharm Sci 1983; 72(6):597-599. (Pubitemid 13062781)
10. Kubota T. 5-fluorouracil and dihydropyrimidine dehydrogenase. Int J Clin Oncol 2003; 8(3):127-131. (Pubitemid 36897281)
11. Kamm YJ, Peters GJ, Hull WE et al. Correlation between 5-fluorouracil metabolism and treatment response in two variants of C26 murine colon carcinoma. Br J Cancer 2003; 89(4):754-762. (Pubitemid 37076185)
12. van der Wilt CL, Marinelli A, Pinedo HM et al. The effect of different routes of administration of 5-fluorouracil on thymidylate synthase inhibition in the rat. Eur J Cancer 1995; 31A(5):754-760.
13. DeAngelis LM, Posner JB. Neurologic complications of cancer. 2nd ed. Oxford University Press, 2009.
14. Guarneri V, Frassoldati A, Giovannelli S et al. Primary systemic therapy for operable breast cancer: a review of clinical trials and perspectives. Cancer Lett 2007; 248(2):175-185. (Pubitemid 46330551)
15. Guarneri V, Conte PF. The curability of breast cancer and the treatment of advanced disease. Eur J Nucl Med Mol Imaging 2004; 31(Suppl 1):S149-161. (Pubitemid 38833045)
16. Kerr IG, Zimm S, Collins JM et al. Effect of intravenous dose and schedule on cerebrospinal fluid pharmacokinetics of 5-fluorouracil in the monkey. Cancer Res 1984; 44(11):4929-4932. (Pubitemid 15204443)
17. Bourke RS, West CR, Chheda G et al. Kinetics of entry and distribution of 5-fluorouracil in cerebrospinal fluid and brain following intravenous injection in a primate. Cancer Res 1973; 33(7):1735-1746.
18. Scherwath A, Mehnert A, Schleimer B et al. Neuropsychological function in high-risk breast cancer survivors after stem-cell supported high-dose therapy versus standard-dose chemotherapy: evaluation of long-term treatment effects. Ann Oncol 2006; 17(3):415-423. (Pubitemid 43329577)
19. Schagen SB, van Dam FS, Muller MJ et al. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 1999; 85(3):640-650. (Pubitemid 29075285)
20. Falleti MG, Sanfilippo A, Maruff P et al. The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature. Brain Cogn 2005; 59(1):60-70. (Pubitemid 41405841)
21. Brezden CB, Phillips KA, Abdolell M et al. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 2000; 18(14):2695-2701. (Pubitemid 30463551)
22. Greenwald ES. Letter: Organic mental changes with fluorouracil therapy. Jama 1976; 235(3):248-249.
23. Lynch HT, Droszcz CP, Albano WA et al. "Organic brain syndrome" secondary to 5-fluorouracil toxicity. Dis Colon Rectum 1981; 24(2):130-131. (Pubitemid 11113362)
24. Atkins JN, Muss HB, Case D et al. High-dose 24-hour infusion of 5-fluorouracil in metastatic prostate cancer. A phase II trial of the Piedmont Oncology Association. Am J Clin Oncol 1991; 14(6):526-529.
25. Anderson-Hanley C, Sherman ML, Riggs R et al. Neuropsychological effects of treatments for adults with cancer: a meta-analysis and review of the literature. J Int Neuropsychol Soc 2003; 9(7):967-982. (Pubitemid 37428441)
26. Peterson CC, Johnson CE, Ramirez LY et al. A meta-analysis of the neuropsychological sequelae of chemotherapy-only treatment for pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer 2008; 51(1):99-104. (Pubitemid 351717398)
27. Stewart A, Bielajew C, Collins B et al. A meta-analysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer. Clin Neuropsychol 2006; 20(1):76-89.
28. Collins B, Mackenzie J, Stewart A et al. Cognitive effects of chemotherapy in postmenopausal breast cancer patients 1 year after treatment. Psychooncology 2009; 18(2):134-143.
29. Wefel JS, Lenzi R, Theriault R et al. 'Chemobrain' in breast carcinoma?: a prologue. Cancer 2004; 101(3):466-475.
30. Dere E, Huston JP, De Souza Silva MA. The pharmacology, neuroanatomy and neurogenetics of one-trial object recognition in rodents. Neurosci Biobehav Rev 2007; 31(5):673-704. (Pubitemid 46670336)
31. Ennaceur A, Meliani K. A new one-trial test for neurobiological studies of memory in rats. III. Spatial vs nonspatial working memory. Behav Brain Res 1992; 51(1):83-92.
32. D'Hooge R, De Deyn PP. Applications of the Morris water maze in the study of learning and memory. Brain Res Brain Res Rev 2001; 36(1):60-90. (Pubitemid 32763130)
33. Deacon RM, Rawlins JN. T-maze alternation in the rodent. Nat Protoc 2006; 1(1):7-12.
34. Tannock IF, Ahles TA, Ganz PA et al. Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J Clin Oncol 2004; 22(11):2233-2239. (Pubitemid 41095159)
35. Lee I, Hunsaker MR, Kesner RP. The role of hippocampal subregions in detecting spatial novelty. Behav Neurosci 2005; 119(1):145-153. (Pubitemid 40279505)
36. Mustafa S, Walker A, Bennett G et al. 5-Fluorouracil chemotherapy affects spatial working memory and newborn neurons in the adult rat hippocampus. Eur J Neurosci 2008; 28(2):323-330.
37. Gandal MJ, Ehrlichman RS, Rudnick ND et al. A novel electrophysiological model of chemotherapy-induced cognitive impairments in mice. Neuroscience 2008; 157(1):95-104.
38. Winocur G, Vardy J, Binns MA et al. The effects of the anti-cancer drugs, methotrexate and 5-fluorouracil, on cognitive function in mice. Pharmacol Biochem Behav 2006; 85(1):66-75. (Pubitemid 44802737)
39. Lee GD, Longo DL, Wang Y et al. Transient improvement in cognitive function and synaptic plasticity in rats following cancer chemotherapy. Clin Cancer Res 2006; 12(1):198-205. (Pubitemid 43166195)
40. Mayer AR, Hanlon FM, Franco AR et al. The neural networks underlying auditory sensory gating. Neuroimage 2009; 44(1):182-189.
41. Kreukels BP, Schagen SB, Ridderinkhof KR et al. Electrophysiological correlates of information processing in breast-cancer patients treated with adjuvant chemotherapy. Breast Cancer Res Treat 2005; 94(1):53-61. (Pubitemid 41416942)
42. Foley JJ, Raffa RB, Walker EA. Effects of chemotherapeutic agents 5-fluorouracil and methotrexate alone and combined in a mouse model of learning and memory. Psychopharmacology (Berl) 2008; 199(4):527-538.
43. Ponnusamy R, Poulos AM, Fanselow MS. Amygdala-dependent and amygdala-independent pathways for contextual fear conditioning. Neuroscience 2007; 147(4):919-927. (Pubitemid 47102540)
44. Huff NC, Rudy JW. The amygdala modulates hippocampus-dependent context memory formation and stores cue-shock associations. Behav Neurosci 2004; 118(1):53-62. (Pubitemid 38222523)
45. Malin EL, McGaugh JL. Differential involvement of the hippocampus, anterior cingulate cortex and basolateral amygdala in memory for context and footshock. Proc Natl Acad Sci USA 2006; 103(6):1959-1963. (Pubitemid 43228800)
46. Rudy JW, Huff NC, Matus-Amat P. Understanding contextual fear conditioning: insights from a two-process model. Neurosci Biobehav Rev 2004; 28(7):675-685. (Pubitemid 39535865)
47. Imayoshi I, Sakamoto M, Ohtsuka T et al. Continuous neurogenesis in the adult brain. Dev Growth Differ 2009.
48. Jessberger S, Clark RE, Broadbent NJ et al. Dentate gyrus-specific knockdown of adult neurogenesis impairs spatial and object recognition memory in adult rats. Learn Mem 2009; 16(2):147-154.
49. Lledo PM, Merkle FT, Alvarez-Buylla A. Origin and function of olfactory bulb interneuron diversity. Trends Neurosci 2008; 31(8):392-400.
50. Han R, Yang YM, Dietrich J et al. Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system. J Biol 2008; 7(4):12.
51. Cho KH, Choi SM, Kim BC et al. 5-fluorouracil-induced oligodendrocyte death and inhibitory effect of cycloheximide, Trolox and Z-VAD-FMK in murine cortical culture. Cancer 2004; 100(7):1484-1490.
52. Zhao C, Deng W, Gage FH. Mechanisms and functional implications of adult neurogenesis. Cell 2008; 132(4):645-660. (Pubitemid 351253687)
53. Mignone RG, Weber ET. Potent inhibition of cell proliferation in the hippocampal dentate gyrus of mice by the chemotherapeutic drug thioTEPA. Brain Res 2006; 1111(1):26-29. (Pubitemid 44331189)
54. Lipsky RH, Marini AM. Brain-derived neurotrophic factor in neuronal survival and behavior-related plasticity. Ann N Y Acad Sci 2007; 1122:130-143. (Pubitemid 350249544)
55. Abraham J, Haut MW, Moran MT et al. Adjuvant chemotherapy for breast cancer: effects on cerebral white matter seen in diffusion tensor imaging. Clin Breast Cancer 2008; 8(1):88-91. (Pubitemid 351346234)
56. Tha KK, Terae S, Sugiura M et al. Diffusion-weighted magnetic resonance imaging in early stage of 5-fluorouracil-induced leukoencephalopathy. Acta Neurol Scand 2002; 106(6):379-386. (Pubitemid 36020748)
57. Seigers R, Schagen SB, Beerling W et al. Long-lasting suppression of hippocampal cell proliferation and impaired cognitive performance by methotrexate in the rat. Behav Brain Res 2008; 186(2):168-175. (Pubitemid 350122748)
58. Dietrich J, Han R, Yang Y et al. CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J Biol 2006; 5(7):22.
59. Antoni MH, Lechner S, Diaz A et al. Cognitive behavioral stress management effects on psychosocial and physiological adaptation in women undergoing treatment for breast cancer. Brain Behav Immun 2008.
60. Lynch G, Rex CS, Chen LY et al. The substrates of memory: defects, treatments and enhancement. Eur J Pharmacol 2008; 585(1):2-13.
61. Ferguson RJ, Ahles TA, Saykin AJ et al. Cognitive-behavioral management of chemotherapy-related cognitive change. Psychooncology 2007; 16(8):772-777. (Pubitemid 47249179)
62. Chamberlain SR, Muller U, Robbins TW et al. Neuropharmacological modulation of cognition. Curr Opin Neurol 2006; 19(6):607-612. (Pubitemid 44760446)
63. Barton D, Loprinzi C. Novel approaches to preventing chemotherapy-induced cognitive dysfunction in breast cancer: the art of the possible. Clin Breast Cancer 2002; 3(Suppl 3):S121-127.